FDA-approved oral AML therapy could let older patients avoid monthly infusion visits

MedicalXpress | 六月 03, 2026

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment. In the international Phase I/Phase II trial led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, Yale University and MD Anderson Cancer Center, patients took a regimen of two pills, decitabine-cedazuridine and venetoclax, with strong response rates and survival outcomes.